Effektivitet og sikkerhed ved rekombinant botulinumtoksin Type A (Eveotox) til injektion til behandling af moderat til svære glabellære linjer
En klinisk fase 3 -undersøgelse for at evaluere effektiviteten og sikkerheden ved rekombinant botulinumtoksin Type A til injektion (Eveotox) sammenlignet med en enkelt behandling af Botox og placebo, og gentagen behandling af Eveotox i moderat til svære glabellare linjer
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Danhua Lin
- Telefonnummer: 15811460241
- E-mail: danhua.lin@jhm-biopharma.com
Undersøgelse Kontakt Backup
- Navn: Lei Wang
- E-mail: lei.wang@jhm-biopharma.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking University First Hospital
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking University Third Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina
- Rekruttering
- The First Affiliated Hospital of Chongqing Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- The First Affiliated Hospital of Jinan University
-
Guangzhou, Guangdong, Kina
- Rekruttering
- The Third Affiliated Hospital of Sun Yat-sen University
-
-
Hebei
-
Shijiazhuang, Hebei, Kina
- Rekruttering
- The First Hospital of Hebei Medical University
-
-
Hunan
-
Changsha, Hunan, Kina
- Rekruttering
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Xuzhou, Jiangsu, Kina
- Rekruttering
- The Affiliated Hospital of Xuzhou Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Rekruttering
- Huashan Hospital, Fudan University
-
-
Shanxi
-
Xianyang, Shanxi, Kina
- Rekruttering
- Xianyang Hospital of Yan'an University
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Rekruttering
- West China Hospital, Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Rekruttering
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Zhejiang Provincial People's Hospital
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female subjects who are between 18 to 65 years of age
- Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale
- Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale
- Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial
Exclusion Criteria:
- Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug
- Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening
- Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety
- Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Eveotox
Eveotox, 20 Units, divided into five injections into the glabellar area. Administered in double-blind fashion at cycle 1 followed by up to 3 open-label cycles. |
Rcombinant botulinum toxin type A for injection(Eveotox) |
|
Aktiv komparator: OnabotulinumtoxinA (Botox )
Botox,20 Units, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units). |
OnabotulinumtoxinA (Botox) |
|
Placebo komparator: Placebo
Placebo, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units) |
Placebo |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Outcome Measure
Tidsramme: Within 4 weeks
|
Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit relative to baseline, based on both the investigators´ and the subjects´ in-clinic assessments. |
Within 4 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary Outcome Measure
Tidsramme: Within 52 weeks
|
Incidence of serious adverse events and drug-related adverse events during the study. |
Within 52 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- JHM03-CT301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .